Right now, there are a number of treatment options available for mantle cell lymphoma (MCL): chemotherapy (with/without immunotherapy), stem cell transplants, and targeted therapy. Yet despite these options, this…
According to a story from BioPharma Dive, the drug company AbbVie has recently announced its decision to withdraw two different approvals for its cancer therapy Imbruvica. The approvals were withdrawn…
For many people living with mantle cell lymphoma (MCL), the standards-of-care include Bruton's tyrosine kinase (BTK) inhibitors. But there is a subset of patients who do not respond well,…
Orphan Drug designation is granted by the FDA to drugs or biologics intended to treat, diagnose, or prevent a rare disease or condition. “Rare,” in the United States, is…
Med City News published an article by Bruce Feinberg, M.D. at Cardinal Heath, examining CAR-T treatments and the impact they have had in medicine during the past five years. CAR-T's…
Dr. Jose Sandoval-Sus, an oncologist at the Moffitt Cancer Center, was recently interviewed with Medscape regarding his review which was published in the October 2022 Current Oncology Reports. The new…
According to a press release that can be found on AP News, new data have been released on a potential treatment - called NVG-111 - for both mantle cell lymphoma…
According to a story from AJMC, the drug developer Incyte has made the decision to withdraw its New Drug Application (NDA) for its investigational therapy parsaclisib. This therapy was submitted…
LOXO-305 is an investigational Bruton’s tyrosine kinase (BTK) inhibitor which is currently in development for the treatment of mantle cell lymphoma (MCL). The next step is to evaluate LOXO-305 in…
Incyte has withdrawn its New Drug Application (NDA) for parsaclisib, which is an investigational treatment for various types of lymphoma, including relapsed/refractory mantle cell lymphoma (MCL), follicular lymphoma, and marginal…
The FDA will review parsaclisib as a treatment for Non-Hodgkin lymphoma (NHL) after accepting Incyte's New Drug Application (NDA). Specifically, the NDA was submitted for the treatment of relapsed or…
BRUKINSA (zanubrutinib), an orally administered Bruton's tyrosine kinase (BTK) inhibitor, has been approved in various countries for the treatment of mantle cell lymphoma (MCL), Waldenström's macroglobulinemia, and marginal zone lymphoma. For…
CAR T-cell therapy has been used as a treatment for a variety of rare diseases including relapsed or refractory diffuse large B-cell lymphoma (DLBCL), non-Hodgkin lymphoma (NHL), as well as…
Even though some patients have the same condition, the treatment plan differs. Why is that? Cure Today spoke to Dr. Elizabeth Bengtson, MD, a hematology expert, to learn more…
In a video posted on OncLive, Dr. Anita Kumar, a medical oncologist, discusses different considerations that must come into play when choosing a treatment for people living with relapsed/refractory mantle…
Patients with relapsed or refractory mantle cell lymphoma (R/R MCL) may have a new treatment option, based on positive results from a Phase 1/2 trial of Zanubrutinib published in Blood…
According to the Cancer Network, orelabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, was recently granted Breakthrough Therapy designation within the United States. While the treatment is also indicated for patients…
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
Transcription factor SOX 11 is encoded by the SOX11 gene. Altogether, this protein is known to play a role in embryonic neurogenesis and tissue formation. However, an estimated 90% of patients with…
Michael E. Williams from the University of Virginia has just been awarded the Mantle Cell Lymphoma Leadership Award by the Lymphoma Research Foundation. This award represents not only his dedication…
New research has demonstrated the importance for understanding risks of bleeding, cardiovascular issues, nonadherence (due to the twice a day dosing), as well as gastrointestinal AE's when deciding to use…
In a recent press release, Kite, a biopharmaceutical company that is part of Gilead Sciences, announced one-year follow-up results from the ZUMA-2 clinical trial. Within the trial, researchers evaluated Tecartus…
According to a story from BioSpace, the biopharmaceutical company Kite announced recently that the Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency, has released…
According to a story from curetoday.com, patients living with mantle cell lymphoma, a rare form of blood cancer that makes up only around six percent of diagnosed non-Hodgkin lymphoma cases…
A recent article in The American Journal of Managed Care (AJMC) heralds the approval of a third CAR T-cell therapy, called Tecartus. Kite Pharma’s cell-based gene therapy is the first…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
